Weijia Fang, MD, and Guoqiang Ai, MD, on the Future of IMC001 in Gastric and Colorectal Cancer

Video

Fang commented on a limitation of the clinical trial pointed out at the European Society for Medical Oncology (ESMO) 2022 Congress.

“Our principle using the bridging drug is only to stabilize. We do not hope to choose a very effective method to make our patient better... in fact, we cannot do that because in the cell therapy stage we definitely have no very good choice.”

At the European Society for Medical Oncology (ESMO) 2022 Congress, September 9-13, 2022, in Paris, France, Weijia Fang, MD, Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University, presented data from a phase 1 clinical trial (NCT05028933) for IMC001, an investigational chimeric antigen receptor (CAR) T-cell therapy which targets the EpCAM protein. The ongoing clinical trial is treating patients with advanced gastric and colorectal cancers who have no standard treatment options remaining.

In an interview with CGTLive, Fang commented on a limitation of the clinical trial’s design that was pointed out by Alessandra Curioni, MD, Center of Hematology and Oncology, University Hospital Zurich, during an invited discussion of the study presentation at ESMO. The limitation related to the use of a bridging chemotherapy before the administration of IMC001.

Guoqiang Ai, MD, Immunofoco Biotech Co., also joined the interview to expand on future plans for the clinical trial, describing the planned second stage, which will combine IMC001 with radiofrequency or microwave ablation therapy. Fang rounded out the interview by discussing potential future research into methods of determining which patients can benefit most from cell therapies, mentioning liquid biopsy as an area of interest.

For more coverage of ESMO 2022, click here. 

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.